Sandra Van Schaeybroeck

Phone+44 (0)28 9097 2954
Emails.vanschaeybroeckqub.acuk

Room 03.010 - PGJCCR
United Kingdom

Accepting PhD Students

PhD projects

Dr. Van Schaeybroeck is interested in PhD applications from candidates with a basic science or clinical background in the fields of;

- Laboratory based investigations into molecular mechanisms including altered pro-survival signaling pathways in RASMT and BRAFMT CRC
- Discovery of novel resistance mechanisms to therapy mechanisms in RASMT and BRAFMT CRC
- Innovative biomarker development using samples from RASMT and BRAFMT CRC patients

Research activity per year

If you made any changes in Pure these will be visible here soon.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

Dive into the research topics where Sandra Van Schaeybroeck is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Active
3 Finished

R6416CNR: Phase 1B/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients
Van Schaeybroeck, S., Johnston, P., Kennedy, R., Lawler, M., Longley, D., Salto-Tellez, M. & Wilson, R.
01/08/2013 → …
Project: Research
R1938CNR: Development of biomarkers for inhibitors of GRP78, the master regulator of the unfolded protein response, for poor prognostic colorectal cancer subgroups.
Van Schaeybroeck, S. & Kennedy, R.
06/09/2018 → 30/09/2020
Project: Research
R1290CNR: Development of EGFR Targeted Camptothecin-Loaded Nanoparticles for Targeting Kras Wild-Type Colorectal Cancer
Longley, D., Scott, C. & Van Schaeybroeck, S.
01/08/2012 → 30/09/2014
Project: Research
R6383CNR: Apoptosis Modelling for Treatment Decisions in Colorectal Cancer
Van Schaeybroeck, S., Johnston, P. & Longley, D.
01/08/2012 → 31/10/2014
Project: Research

53 Article
25 Conference contribution
14 Meeting abstract
2 Chapter (peer-reviewed)
More
- 1 Chapter
- 1 Review article

Bcl-xL is a key mediator of apoptosis following KRAS^G12C inhibition in KRAS^G12C-mutant colorectal cancer
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S. & Van Schaeybroeck, S., 01 Jan 2023, In: Molecular Cancer Therapeutics. 22, 1, p. 135–149 15 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
24 Downloads (Pure)
USP17 is required for peripheral trafficking of lysosomes
Lin, J., McCann, A., Sereesongsaeng, N., Burden, J., Alsa'd, A. A. M., Burden, R., Micu, I., Williams, R., Van Schaeybroeck, S., Evergren, E., Mullan, P., Scott, C. & Burrows, J., 26 Jan 2022, In: EMBO Reports.
Research output: Contribution to journal › Article › peer-review

Open Access
File
170 Downloads (Pure)
An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution
Lindner, A. U., Salvucci, M., McDonough, E., Cho, S., Stachtea, X., O'Connell, E. P., Corwin, A. D., Santamaria-Pang, A., Carberry, S., Fichtner, M., Van Schaeybroeck, S., Laurent-Puig, P., Burke, J. P., McNamara, D. A., Lawler, M., Sood, A., Graf, J. F., Rehm, M., Dunne, P. D., Longley, D. B., & 2 othersGinty, F. & Prehn, J. H. M., 09 Nov 2021, (Early online date) In: Cell death and differentiation.
Research output: Contribution to journal › Article › peer-review

Open Access
File
30 Downloads (Pure)
A Nudibranch Marine Extract Selectively Chemosensitizes Colorectal Cancer Cells by Inducing ROS-Mediated Endoplasmic Reticulum Stress
Ruiz-Torres, V., Forsythe, N., Pérez-Sánchez, A., Van Schaeybroeck, S., Barrajón-Catalán, E. & Micol, V., 08 Apr 2021, In: Frontiers in Pharmacology. 12, 18 p., 625946.
Research output: Contribution to journal › Article › peer-review

Open Access
File
55 Downloads (Pure)
Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer
McCann, C., Matveeva, A., McAllister, K., Van Schaeybroeck, S., Sessler, T., Fichtner, M., Carberry, S., Rehm, M., Prehn, J. H. M. & Longley, D. B., Sep 2021, In: The FEBS Journal. 288, 18, p. 5374-5388
Research output: Contribution to journal › Article › peer-review

Open Access
File
1 Citation (Scopus)

9 Downloads (Pure)

Targeting poor prognostic molecular subtypes in colorectal cancer
Sandra Van Schaeybroeck (Keynote speaker)
17 May 2019
Activity: Talk or presentation types › Invited talk
Daniel Hochhauser
Sandra Van Schaeybroeck (Host)
09 May 2019
Activity: Hosting a visitor types › Hosting an academic visitor
COLOSSUS CRC PPI event at RCSI
Sandra Van Schaeybroeck (Keynote speaker)
30 Apr 2019
Activity: Talk or presentation types › Invited talk
Internal examiner
Sandra Van Schaeybroeck (Examiner)
2019
Activity: Examination types › Other examination
Molecular Cancer Therapeutics (Journal)
Sandra Van Schaeybroeck (Peer reviewer)
25 Sep 2018
Activity: Publication peer-review and editorial work types › Publication peer-review

Queen’s researchers discover ground-breaking process which destroys bowel cancer cells
Sandra Van Schaeybroeck, P.G. Johnston, P.G. Johnston & P.G. Johnston
06/09/2018
8 items of Media coverage
Press/Media: Research
RESEARCHERS FIND KEY TO DRUG RESISTANT BOWEL CANCER
Sandra Van Schaeybroeck
08/11/2016
2 items of Media coverage
Press/Media: Research
Queen’s leads €6million European study to combat bowel cancer
Sandra Van Schaeybroeck
14/12/2013
1 item of Media coverage
Press/Media: Research

Sandra Van Schaeybroeck

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

R6416CNR: Phase 1B/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients

R1938CNR: Development of biomarkers for inhibitors of GRP78, the master regulator of the unfolded protein response, for poor prognostic colorectal cancer subgroups.

R1290CNR: Development of EGFR Targeted Camptothecin-Loaded Nanoparticles for Targeting Kras Wild-Type Colorectal Cancer

R6383CNR: Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

Bcl-xL is a key mediator of apoptosis following KRAS^G12C inhibition in KRAS^G12C-mutant colorectal cancer

USP17 is required for peripheral trafficking of lysosomes

An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution

A Nudibranch Marine Extract Selectively Chemosensitizes Colorectal Cancer Cells by Inducing ROS-Mediated Endoplasmic Reticulum Stress

Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer

Targeting poor prognostic molecular subtypes in colorectal cancer

Daniel Hochhauser

COLOSSUS CRC PPI event at RCSI

Internal examiner

Molecular Cancer Therapeutics (Journal)

Queen’s researchers discover ground-breaking process which destroys bowel cancer cells

RESEARCHERS FIND KEY TO DRUG RESISTANT BOWEL CANCER

Queen’s leads €6million European study to combat bowel cancer

Sandra Van Schaeybroeck

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output

Activities

Press/Media